Firering Strategic Minerals: From explorer to producer. Watch the video here.
I'm interested in views from our more informed members here as to whether this announcement in the budget as reported today in the Economist could be helpful to ReNeuron. The article sub headed |"Britain commits to finding a regulatory route for customised genetic medicines" the article stated - "The headlines about the autumn statement from Jeremy Hunt, the chancellor, this week focused on tax and spending. But tucked away in the written documents was news that could transform the cutting-edge of medicine. The Medicines and Health-care products Regulatory Agency (mhra) is working with Genomics England, Oxford University and Mila’s Miracle Foundation, a charity, to develop a regulatory pathway to allow one-off drugs to be designed and approved for use in individual patients in less than a year.
Medicines currently travel a well-worn route to market comprising two or three phases of trials in large groups of patients. But this approach is impossible for the vast majority of genetic disorders, which are often vanishingly rare or even unique. The technology to customise medicines for people with such conditions exists but the regulatory route they must take is rocky.....etc" Couls this be an additional encouragement to get a deal across the line and what Ian has been waiting for? Surely this must offer some hope to striking one or more DEALS, PARTNERSHIPS, INVESTMENT, ASSET REVALUATION. THose with better knowledge maybe able to provide greater insight here PLEASE COMMENT IF SO. The link to the article is: https://www.economist.com/britain/2023/11/22/the-worlds-first-pathway-for-individually-designed-drugs?utm_campaign=a.the-economist-today&utm_medium=email.internal-newsletter.np&utm_source=salesforce-marketing-cloud&utm_term=11/22/2023&utm_id=1830040 THANK YOU.
Appreciate lack of resources has meant shelving of initial trials for stroke in favour of Exosomes, but we had a phase 2 trial, which was reviewed by the BBC showing the patient Leonard and his improvements from the ReNeuron stem cell injections - ref https://www.reneuron.com/news-list/bbc-breakfast-news-interview-stem-cells-used-in-stroke-treatment/ - This was powerful stuff from the back catalogue and still would merit an update on Lenard's progress and whether he is now touching his nose with his left hand and walking better? Would provide confidence knowing that work by Fosum is still active on this? The BBC indicated they would like to follow up on progress, could be very effective low cost PR which if achieved would greatly assist partner deal and fund raising. Indeed a clever deal with The British Heart Foundation who are a cardiovascular research charity in the United Kingdom, with a donation of future profits percentage would also be a clever move! I hope this is picked up by new management team.
Todays Guardian has a review of ‘Cancer and Heart disease vaccines ready by end of the decade….’ If only this article gave indication it was made possible by use of ReNeuron Exosomes … see https://www.theguardian.com/society/2023/apr/07/cancer-and-heart-disease-vaccines-ready-by-end-of-the-decade?CMP=Share_iOSApp_Other
I viewed a treatment using a re-engineered polio virus to kill cancer cells, I wonder is this something to which ReNeuron exosomes could help improve efficiencies, I am way out of my depth but given we can cross the brain barrier just maybe there is something here? It is worth a view and would appreciate a more informed or qualified assessment. See https://youtu.be/FEA6BQARqE8
This clip of Warren Buffet advice made me think of ReNeuron long suffering shareholders let us hope.
https://youtube.com/shorts/GS2kIfo5NQw?feature=share
Thank you Phil, for bringing clarity here.
Appreciated Phil, it was the mention of exploring cancer treatments which caught my attention. Thanks Clive
I was intrigued by the article on the BBC website and if this could be one of the partnerships or indeed be a potential partnership for ReNeuron’s unique effective delivery Exosomes platform so would be interested in any views from wiser members here to advise?
BioNTech: Could Covid vaccine technology crack cancer? https://www.bbc.co.uk/news/health-63247997
Fantastic announcement today by ReNeuron making Catherine their new CEO a well deserved and merited appointment of a well qualified and experienced individual to lead and ‘bring home’ the success we all desire. Congratulations Catherine go build the winning team and business!
The share options are granted at 31.5p buy in from directors when executing, without reading the actual terms I think this means they have freedom to strike one big deal off, ie say they have a couple of players for Exosomes lined up, one option maybe to sell used this to negotiate a controlling stake sell with new money at an even higher price point so as to allow the acquirer to buy exclusivity in certain markets and product offerings, ie get an even greater premium. Options usually form part of acquisition ie they need to be exercised at point of purchase. This allows flexibility in my opinion on this teams negotiation position. Their entry point is 31.5p which without them we have no chance so I don’t begrudge them, I want them free to maximise there potential earnings. From a 5p pre 100/1 consolidation we are looking for at a £5 price built that is well into the furture and contingent on successful outcomes on what is still an early stage NPD programme + patent assets. Not worth speculating on any future share price at moment just have to trust skill and judgement of team in play. (Again it is only my opinion as an ex PLC CEO and my own research and thoughts on the team and their technology opportunity)
I don’t disagree with the sentiment and frustration but this team is onboard only 6+ months, and I can only speak for myself and the research I have done on those individuals, to say I feel comfortable at last we have a strong commercial leaders in the key functions required to make things happen. These next twelve months will need to see deal deliverables to recover a pathway to a sensible valuation and share price, but for someone here since 2015 I have bought more to average out and still am substantially down, but remain patient not to sell and see it through. (Clearly all views are my own, please do your own research).
Todays announcement of share options will go a long way to rebuilding confidence in the new team key players and shows confidence to a base price of 31.5p from which to build up. ‘ The Options granted under The Plans have an exercise price of 31.5 pence per share, being the closing mid-market price of the Company's shares on 13 July 2022. The Options vest in equal proportions at 12, 24 and 36 months from the date of grant. None of the Options are subject to the achievement of performance conditions.’
I would expect as part of a planned purchase that you will see further director share purchases ahead of AGM and full results announcement maybe by end of July. I know if it were me I would have a planned programme over a few weeks to maximise share moves rather than blow all in one go. At present any gain is eroded by other investor sales and this needs to be corrected. The share price needs careful marketing to rebuild ahead of a deal announcement over time.
Thank you for the views, what I take more than anything from this is that the deal is moving forward, whilst I appreciate a lot expect more, my view is that this deal is China on CTX Stroke and Fosun have committed considerable resource and finance to building a bespoke plant to produce/manufacture the ReNeuron product and they say this will be done in quarter 1 - 2023 so that is quite something as we will receive a high percentage engage of sales value as stated in the contract (is its 20%?). So if we had more up front we may have received less on the percentage commission. I am looking forward to Monday and how the new strategy is unfolding.
Sajy, In support of your rationale I would share a link to a paper produced in part by Dr. Randolph Corteling supporting the thought of getting back to basics and the Fosum arrangement etc. Exosomes from neuronal stem cells may protect the heart from ischaemia/reperfusion injury via JAK1/2 and gp130 - link https://onlinelibrary.wiley.com/doi/epdf/10.1111/jcmm.16515
The RNS today shows a hardening of commercial management, Martin Walton is a partner/fellow director of Professor Sir Chris Evans in Excalibur Medicines Ltd, who whilst stepping down from the ReNeuron board last year invested a further £1m at £0.70 in the last fund raising. So far from signalling a fund raise it is more compelling Martin with his experience is an appointment to ReNeuron to protect Sir Chris Evan`s investment!
Thank you Sajy, I should also point out that Dr Randolph Corteling who features in the study I posted, will be re-joining ReNeuron this month ref press release ref - https://www.reneuron.com/wp-content/uploads/RENE-Appointment-of-VP-of-research-11.01.22.pdf - he will be key to helping sell the usp’s on ReNeuron Exosomes against our competitors, he will under this new management be given a more spokeperson on this technology given his specialisation. Dr Randolph Corteling has 24 years’ experience in medical research and drug discovery, spanning academia, biotechnology and the pharmaceutical industry. He gained his PhD in Medical and Surgical Sciences at Nottingham University, followed by three years as a Heart and Stroke Foundation Postdoctoral Fellow at the University of Calgary, Canada.
So I believe we will get back to core values for ReNeuron given he originally joined them in 2007. In 2011 he was appointed Head of Cell Biology where he established the first exosome programmes at ReNeuron - so we have the right person being given his head.
Like a lot of posts here it becomes hard to understand how we got here, but it is what it is. I think we have some smart management now in place with our Chairman and science based FD who are commercial first. A lot has not been fully communicated on why certain treatments were closed down and now left to licensing, other than cost. My period of reflection has led to looking at some past info as CTX/Stroke stem cell treatments was my reasoning for investment. This article reported in December 2020 reminds us that actually the Exosomes maybe the most cost effective way of executing already developed on hold treatments along with new.
"Exosomes from neuronal stem cells may protect the heart from ischaemia/reperfusion injury via JAK1/2 and gp130". It is published in the Journal of Cellular and Molecular Medicine this month and involved collaboration between Reneuron, UCL, and The Hebrew University of Jerusalem. Here's the open access link if you're interested : https://onlinelibrary.wiley.com/doi/epdf/10.1111/jcmm.16515
The researchers used Reneuron's CTX0E03 cell line to source the exosomes used in this study. It is interesting to see that exosomes, in this case derived from neuronal stem cells, may have applications beyond the source cell type (in this case heart tissue).
Got me thinking, Olaf was not a charismatic leader able to convey/promote hope in a manner to instil confidence in the investor community. The human factor in leadership. Bottom line there is a lot of value goodwill/asset value in learning and proprietary tech that is not being correctly promoted or presented, but then again I believe some on the board realise this hence the recent changes. The silence at present is not a weakness more a calm considered key new management preparing their next chess move to rebuild confidence, I for one am buying more to further average out my position. This is my personal observations and not a recommendation to others do your own research. Clive, an investor since 2015.
Hi Graffiti, I like your assesment and agree though, I would have expected a move by their chairman and CEO and possibly other board members to have purchased some shares as a means of demonstrating confidence to the market….
Reference my post in December ‘Crisis of Confidence or Poor Communication’ (post in December), referenced the need for transparency with shareholders, now we have the real picture, an oversell has meant the SP hit, has created opportunity for the smart money to move in. The underlying assets and learning in ReNe means it is an interesting partner for delivering treatments just requires a more creative thinking to a commercial opportunities to be explored. I believe some interesting opportunities may now be entertained as this very public episode has provided greater awareness, and brought a more commercial edge to every decision now made. I for line am great full to have the experience, skill of the new Chairman, CFO, CSO and reconnected VP of research. Let us hope the lessons are learned finally and from the ashes the phoenix will rise.